PharmaMar soars 20% in the stock market due to the results of plitidepsin against Covid

PharmaMar he rides one more day on the Ibex 35 due to the results of his investigations against the coronavirus. The latest findings recognized by the journal Science about the chemical compound plitidepsin they are the reason that this Tuesday its shares rise more than 20% in the Madrid park and are above 108 euros.

The prestigious scientific publication has endorsed the “powerful” activity of said compound against Covid-19 in an article that states that the Spanish laboratory test showed a 99% decrease in the SARS-CoV-2 viral loads in the lungs of the animals under study. The magazine also emphasizes that the toxicity that this product would have in human cells is “significantly lower” than that seen in other experiments.

The results are yet another boost to the listing of a company that, since the beginning of the pandemic, has been among the investors’ favorites. Its titles ended 2020 with a 50% revaluation, although there were times during the year when it exceeded 100% and touched 150 euros.

The arrival of the vaccines made them lose steam, but 2021 and the new results have put the company back in the target of the markets. Only in this month of January has it managed to match that 50% accumulated increase and its capitalization reaches 1,980 million euros.

“The studies of PharmaMar and other companies such as the US Gilead they were destined to cure the disease once it was infected, so the introduction of vaccines that would prevent precisely this situation significantly penalized their price. However, in the middle of the third wave, cwith the hospitals saturated again, and in view of the numerous obstacles that the different administrations are encountering in order to vaccinate the population, this news has given a new boost to its price and has led it to exceed important levels in the graph “, he explains Aitor MÃ © ndez, IG Markets analyst.

At the head of the Ibex

The laboratory leads the rises this Tuesday in the Ibex 35, even ahead of Naturgy, which increased by around 15% as a result of the boost from the IFM fund offer to take over 22% of the company.

Bank Sabadell, Merlin Properties and Meliá they are the other protagonists of the session, with increases of over 3% that allow the selective to gain more than 1% and touch 8,000 points again.

At the opposite extreme, Solaria (-7%), Siemens Gamesa and Cellnex They are the worst values ​​of the day and prevent the Spanish index from coming close to the rises of other European markets such as the Dax in Frankfurt (+ 1.9%). The Cac 40 in Paris (+ 1.4%), the Ftse Mib in Milan (+ 1.2%) and the Ftse 100 in London (+ 0.3%) also remained green despite the slowdown in vaccination campaigns and the general increase in infections in Europe.